Research map: Angiotensin-converting enzyme inhibitors show an edge over angiotensin II receptor blockers in cardiovascular outcomes

Back to the article

Papers in this map

  1. Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes · Hermann G. Haller · 2011 · 802 citations · Cited by this paper
  2. Cilostazol for heart rate increase in atrial fibrillation with slow ventricular response: an exploratory randomized controlled trial · 2026 · Related
  3. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients · Laura C. van Vark · 2012 · 459 citations · Cited by this paper
  4. Finerenone vs. spironolactone to reduce adverse outcomes in patients with cardiac–kidney–metabolic syndrome complicated by atrial fibrillation: findings from the Tianjin atrial fibrillation project · 2026 · Related
  5. Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study · Ruijun Chen · 2021 · 194 citations · Cited by this paper
  6. Risk factors for cardiac death in women with coronary artery disease · 2026 · Related
  7. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials · Sripal Bangalore · 2016 · 109 citations · Cited by this paper
  8. Cardiac autonomic function in elderly patients with and without atrial fibrillation · 2026 · Related
  9. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: what is new in pharmacotherapy? · Cian P. McCarthy · 2024 · 96 citations · Cited by this paper
  10. Left bundle branch area pacing: anatomical and physiological features made easy · 2026 · Related
  11. Effect of the Renin-Angiotensin System Inhibitors on Inflammatory Markers: A Systematic Review and Meta-analysis of Randomized Controlled Trials · Kamal Awad · 2022 · 67 citations · Cited by this paper
  12. From simulator to patient: transfer of procedural skills to practice in cardiac device implantation · 2026 · Related
  13. Why Are We Still Prescribing Angiotensin-Converting Enzyme Inhibitors? · Franz H. Messerli · 2022 · 20 citations · Cited by this paper
  14. Asymptomatic and symptomatic cardiac toxicity associated with immune checkpoint inhibitors: insights from a Japanese registry · 2026 · Related
  15. Changes in Utilization of Generic Angiotensin Receptor Blockers Following Product Recalls in the United States · Rishi J. Desai · 2020 · 18 citations · Cited by this paper
  16. Impact of chronic kidney disease on clinical outcomes among patients with atrial fibrillation following percutaneous left atrial appendage occlusion: a multicentre cohort study · 2026 · Related
  17. Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular and non-cardiovascular outcomes in patients at high/very-high cardiovascular risk without heart failure: a systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials · Stefano Masi · 2026 · 2 citations · Cited by this paper
  18. Weight change and long-term cardiovascular outcomes in overweight and obese patients after acute coronary syndromes · 2026 · Related
  19. In Reply: ACEI and ARB — Each Unique RAAS Inhibitors · Kamal Awad · 2023 · 1 citation · Cited by this paper
  20. Association of self-reported sports volume and discipline with atrial arrhythmia prevalence in middle-aged males · 2026 · Related

Source: OpenAlex (CC0)